Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-19b-3p mimic + miR-132-3p mimic + miR-31-5p mimic + miR-92a-3p inhibitor
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Topical
01
Overview
miR-19b-3p mimic + miR-132-3p mimic + miR-31-5p mimic + miR-92a-3p inhibitor is a microRNA (miRNA) cocktail designed to promote diabetic wound healing. Developed by researchers at the Chinese Academy of Medical Sciences and Peking Union College, the cocktail targets multiple critical phases of wound repair, including inflammation, re-epithelialization, granulation tissue formation, and angiogenesis. It comprises locked nucleic acid (LNA)-modified mimics of miR-19b-3p, miR-132-3p, and miR-31-5p, alongside an inhibitor of miR-92a-3p, delivered locally via in vivo-jetPEI. In preclinical murine models of acute and chronic wounds, local application of the cocktail significantly accelerated healing, attenuated inflammatory cytokine expression, reduced macrophage migration, promoted angiogenesis, and facilitated nerve regeneration.
- Other names
- microRNA cocktailmiRNA cocktail
02
Targets
EMP1 (Epithelial membrane protein 1)HBEGF (Heparin-binding EGF-like growth factor)NF-κBPTEN (Phosphatase and tensin homolog deleted on chromosome ten)PAL (Phenylalanine ammonia-lyase)TLR3 (Toll-like receptor 3)miR-92a-3p (microRNA-92a-3p)
Beyond the preview
Go deeper on miR-19b-3p mimic + miR-132-3p mimic + miR-31-5p mimic + miR-92a-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-19b-3p mimic + miR-132-3p mimic + miR-31-5p mimic + miR-92a-3p inhibitor.